Canadian newspapers support mifepristone medical abortion to improve fulfillment of the right to health (2015-2019)

Author:

Kendall Tamil,Sriram Pallavi,Parmar Amrit,Norman Wendy V.ORCID

Abstract

AbstractIn 2015, mifepristone, the international gold standard for medical abortion, was approved for use in Canada. Our content analysis of Canadian newspaper coverage describes arguments in favor or against medical abortion and the evolving regulatory framework for mifepristone from six months before approval until the last province included the medication as a publicly insured health benefit (2015-2019).Our study found an exceptionally high level of support for the approval, introduction and removal of regulatory barriers to mifepristone for medical abortion. Of 402 articles, 67% were pro-medical abortion, 25% presented balanced or neutral coverage and only 8% presented solely anti-medical abortion viewpoints. Of the 761 stakeholders cited, more than 90% made positive or neutral statements about medical abortion. Most articles discussed medical abortion as a health issue and contained arguments about how liberalization of the regulatory framework and public payment for mifepristone would improve abortion availability (68%), accessibility (87%), acceptability (34%) and quality (19%). Mifepristone’s introduction in Canada was presented in newspapers as a way to increase women’s health, specifically in rural areas where disparities in abortion access exist.Rather than formal balance, which presents contrasting arguments as equally valid even when the scientific evidence for one vastly outweighs the other, our study identified evidentiary balance where coverage aligned with the majority of evidence and expert opinion. Our results differ from analyses in other high-income countries (United Kingdom, United States) that have found that media frame abortion as a stigmatized and controversial issue or mention abortion predominantly with respect to electoral politics rather than as a health issue. The Canadian print media presented overwhelmingly favorable arguments towards the expansion of mifepristone medical abortion and served to destigmatize abortion by framing the introduction and universal coverage of medical abortion as fulfilling core components of the right to health.

Publisher

Cold Spring Harbor Laboratory

Reference56 articles.

1. Medical abortion in Canada: behind the times;CMAJ : Canadian Medical Association journal = journal de l’Association medicale canadienne,2014

2. World Health Organization. 19th WHO Model List of Essential Medicines. Available at: https://www.who.int/topics/essential_medicines/en/ Accessed 2019 Mar 242015.

3. World Health Organization. Abortion care guideline. World Health Organization Guidelines. 2022;Licence: CC BY-NC-SA 3.0 IGO(Available at: https://www.who.int/publications-detail-redirect/9789240039483): Geneva.

4. Grant K. Long-awaited abortion pill Mifegymiso makes Canadian debut. The Globe and Mail 2017 Jan 20.

5. Health Canada . Regulatory decision summary: MIFEGYMISO. 2015. Available at https://cart-grac.ubc.ca/np-mifepristone-study/regulatory-decision-summary-sbd_-mifegymiso-2015-health-canada/?login(last Accessed on August 27, 2021). Ottawa, Canada: Government of Canada.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3